Related Experiment Video

Updated: Mar 19, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma

Keiran Sm Smalley1, Inna V Fedorenko2

  • 1Department of Tumor Biology; The Moffitt Cancer Center & Research Institute; Tampa, FL, USA; Department of Cutaneous Oncology; The Moffitt Cancer Center & Research Institute; Tampa, FL, USA.

Molecular & Cellular Oncology
|June 17, 2016
PubMed

Insights

BRAF inhibitor therapy often fails in melanoma patients due to new disease sites. This study reveals that BRAF inhibition triggers a switch to a metastatic phenotype driven by erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • BRAF inhibitor therapy is a standard treatment for melanoma.
  • A significant challenge in melanoma treatment is acquired resistance to BRAF inhibitors.
  • Melanoma patients often develop new metastatic sites after initial treatment response.

Purpose of the Study:

  • To investigate the mechanisms underlying BRAF inhibitor resistance in melanoma.
  • To identify key signaling pathways driving melanoma metastasis upon treatment failure.
  • To explore the role of erythropoietin-producing hepatocellular receptor A2 (EphA2) signaling in treatment-resistant melanoma.

Main Methods:

  • Phosphoproteomic analysis of melanoma cells.
  • In vitro and in vivo models of BRAF inhibitor resistance.
  • Assessment of EphA2 signaling pathway activation.

Main Results:

  • BRAF inhibition induces a phenotypic switch towards an aggressive and metastatic melanoma state.
  • Ligand-independent EphA2 signaling is identified as a critical driver of this switch.
  • The findings implicate EphA2 in the development of new disease sites observed in treatment-resistant melanoma.

Conclusions:

  • BRAF inhibitor resistance in melanoma is associated with a shift to a more aggressive phenotype.
  • EphA2 signaling plays a crucial role in mediating this treatment-induced metastatic switch.
  • Targeting EphA2 signaling may represent a potential therapeutic strategy for overcoming BRAF inhibitor resistance in melanoma.
Keywords:
BRAFephrinmelanomametastasisresistance

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K